Get started
Author

Christopher Montemagno

Observed names: C. Montemagno, Montemagno, Christopher
Observed institutions: Centre National de la Recherche Scientifique, Inserm, Université Côte d'Azur, Centre Hospitalier Universitaire de Grenoble, Karolinska Institutet, Laboratoire Radiopharmaceutiques Biocliniques, Hôpital l'Archet, Centre Méditerranéen de Médecine Moléculaire, Institut de Recherche sur le Cancer et le Vieillissement de Nice, Scientific Centre of Monaco, Centre Antoine Lacassagne, Institut pour l'avancée des biosciences, Communauté Université Grenoble Alpes, Center for Regenerative Therapies Dresden, Biotechnologisches Zentrum, Technische Universität Dresden, Université Grenoble Alpes
ORCID: 0000-0002-5687-1812
Observed ORCID: 0000-0002-5687-1812
OpenAlex ID: A5053641516
Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs
2020 · Christopher Montemagno, Gilles Pagès · Frontiers in Cell and Developmental Biology · 100
PDF
Integrin-αvβ3 as a Therapeutic Target in Glioblastoma: Back to the Future?
2022 · William Echavidre, Vincent Picco, et al. · Pharmaceutics · 70
PDF
Cancer‐associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti‐angiogenic therapy
2021 · Damien Ambrosetti, Michael Coutts, et al. · British Journal of Urology · 59
Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma
2020 · Christopher Montemagno, Anais Hagege, et al. · OncoImmunology · 58
PDF
Integrin Targeting and Beyond: Enhancing Cancer Treatment with Dual-Targeting RGD (Arginine–Glycine–Aspartate) Strategies
2024 · Bojana Bogdanović, Daniel Fagret, et al. · Pharmaceuticals · 49
PDF
Cabozantinib, a Promising Therapeutic Strategy for Resistant Head and Neck Squamous Cell Carcinoma Patients
2021 · Anais Hagege, Esma Saada-Bouzid, et al. · Cell Reports Medicine · 41
PDF
From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma
2020 · Christopher Montemagno, Shamir Cassim, et al. · International Journal of Molecular Sciences · 41
PDF
LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers
2016 · Chloé Prunier, Véronique Josserand, et al. · Cancer Research · 40
PDF
Molecular imaging of liver inflammation using an anti-VCAM-1 nanobody
2023 · Maxime Nachit, Christopher Montemagno, et al. · Nature Communications · 29
PDF
99mTc-A1 as a Novel Imaging Agent Targeting Mesothelin-Expressing Pancreatic Ductal Adenocarcinoma
2019 · Christopher Montemagno, Shamir Cassim, et al. · Cancers · 25
PDF
Evaluation of Antiatherogenic Properties of Ezetimibe Using3H-Labeled Low-Density-Lipoprotein Cholesterol and99mTc-cAbVCAM1–5 SPECT in ApoE−/−Mice Fed the Paigen Diet
2017 · Laurent S. Dumas, François Briand, et al. · Journal of Nuclear Medicine · 25
PDF
Preclinical Evaluation of Mesothelin-Specific Ligands for SPECT Imaging of Triple-Negative Breast Cancer
2018 · Christopher Montemagno, Sandrine Bacot, et al. · Journal of Nuclear Medicine · 23
PDF
Anti-Vascular Endothelial Growth Factor C Antibodies Efficiently Inhibit the Growth of Experimental Clear Cell Renal Cell Carcinomas
2021 · Aurore Dumond, Christopher Montemagno, et al. · Cells · 21
PDF
In Vivo Biodistribution and Efficacy Evaluation of NeoB, a Radiotracer Targeted to GRPR, in Mice Bearing Gastrointestinal Stromal Tumor
2021 · Christopher Montemagno, Florian Raes, et al. · Cancers · 21
PDF
Antiangiogenic Compound Axitinib Demonstrates Low Toxicity and Antitumoral Effects against Medulloblastoma
2021 · Marina Pagnuzzi-Boncompagni, Vincent Picco, et al. · Cancers · 20
PDF
Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma
2021 · Aurore Dumond, Etienne Brachet, et al. · Journal of Experimental & Clinical Cancer Research · 20
PDF
Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001
2024 · Christopher Montemagno, Arnaud Jacquel, et al. · Journal of Experimental & Clinical Cancer Research · 19
PDF
Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?
2021 · Christopher Montemagno, Shamir Cassim, et al. · International Journal of Molecular Sciences · 18
PDF
Should evidence of an autolysosomal de-acidification defect in Alzheimer and Parkinson diseases call for caution in prescribing chronic PPI and DMARD?
2023 · Sandy Giuliano, Christopher Montemagno, et al. · Autophagy · 17
Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?
2020 · Nicolas de Leiris, Julien Leenhardt, et al. · Cancer Imaging · 16
Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future
2023 · William Echavidre, Daniel Fagret, et al. · Cancers · 15
PDF
Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine
2020 · Christopher Montemagno, Gilles Pagès · Cancers · 15
PDF
In Vivo Assessment of VCAM-1 Expression by SPECT/CT Imaging in Mice Models of Human Triple Negative Breast Cancer
2019 · Christopher Montemagno, Laurent Dumas, et al. · Cancers · 12
PDF
Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al. · Cancer Research Communications · 9
A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma
2023 · Christopher Montemagno, Jérôme Durivault, et al. · Molecular Oncology · 9
PDF
Works count: 99
Citation count: 806
H-index: 18
I10-index: 23
Year
Topic
Type